AiVita Biomedical, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Irvine CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03400917
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AIVITA Biomedical | Aivita Biomedical, Inc. | PT AIVITA Biomedika Indonesia

Active Ingredients

Drugs in Phase 3 Trials (2)

autologous monocytes (1 trial)

av-gbm-1 (2 trials)

Drugs in Phase 2 Trials (1)

av-covid-19 (4 trials)

Drugs in Phase 1 Trials (2)

av-mel-1 (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Infections (Phase 1)

Melanoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5